Routine genomic profiling in NSCLC provides clinically relevant information beyond actionable driver detection when interpreted together with stage, smoking history, age, sex, and regional molecular context, and support a more context-aware interpretation of routine molecular diagnostics in thoracic oncology.
Abstract
Background Routine targeted genomic profiling in non-small cell lung cancer (NSCLC) is primarily used to identify actionable alterations but may provide more information for clinical decision making. In this study routine genomic profiling data were used to examine the mutational landscape of lung cancer and its relationship to patient characteristics. Materials and methods We analyzed Archer VariantPlex 67-gene sequencing data from 528 patients diagnosed with lung cancer in the North Swedish Health Care Region between 2011 and 2021 and linked the genomic results to registry-derived clinical and demographic data. Mutation frequencies, positional architectures, subgroup enrichments, and survival associations were compared within the regional cohort and against an external reference cohort assembled from cBioPortal. Results After quality filtering, 1,415 somatic variants across 60 genes were identified, with a mean of 2.68 mutations per tumor, indicating substantial heterogeneity in mutational profiles. TP53 and KRAS formed a conserved mutational backbone across cohorts, whereas EGFR was less frequent and MET, APC, ATM, and CDKN2A were enriched in North Sweden relative to the external reference cohort. Major hotspot architectures were broadly preserved, although MET showed the clearest positional divergence. Mutation patterns varied by age, sex, smoking status, and disease stage. EGFR defined the most coherent clinical subtype, being enriched in females, never-smokers, younger patients, and earlier-stage disease, whereas KRAS, STK11, and TP53 were associated with smoking. EGFR was the strongest favorable prognostic marker, but stage strongly influenced the interpretation of many survival differences, indicating that gene-level prognostic signals are closely shaped by clinical context. Conclusions Routine genomic profiling in NSCLC provides clinically relevant information beyond actionable driver detection when interpreted together with stage, smoking history, age, sex, and regional molecular context. These findings support a more context-aware interpretation of routine molecular diagnostics in thoracic oncology.
BACKGROUND
Cancer is the leading cause of disease-related mortality in children. Next-generation sequencing (NGS) has emerged as a critical tool in precision oncology, enabling the identification of somatic genomic alterations that may inform diagnosis, prognosis, and therapy. This study evaluated the clinical utility...
H. Cohen, Iris Kventsel, S. Caspi et al.· Pediatric Research· 0 citations
Objectives: Precision medicine has improved outcomes in advanced lung cancer, but its implementation remains limited. The prospective LANTERN project (NCT05802771) involves comprehensive clinical and multi-omics data collection. Here, we report preliminary genomic findings, focusing on the prognostic impact of gene mut...
C. Sassorossi, E. De Paolis, Jessica Evangelista et al.· Genes· 0 citations
The routine implementation of comprehensive genomic profiling in metastatic HER2-negative breast cancer, especially in metastatic HER2-negative breast cancer, is supported to guide precision oncology strategies and enable enrollment in biomarker-driven clinical trials.
E. Papadopoulou, M. Stathoulopoulou, M. Matiatou et al.· Cancer Genomics & Proteomics· 0 citations
BACKGROUND
The clinical characteristics of BRCA1 and BRCA2 (BRCA) deleterious alterations in advanced prostate cancer-considering age, family history, co-occurring gene alterations, and variant type-remain incompletely understood in patients undergoing tumor-only panel testing.
MATERIALS AND METHODS
We analyzed 2,815...
H. Tsumura, D. Koguchi, K. Tabata et al.· The Prostate· 0 citations
A large-scale real-world study demonstrates the heterogeneous molecular landscape of advanced NSCLC and identifies clinically relevant co-alteration patterns involving EGFR, KRAS, STK11, MET, and PIK3CA involving EGFR, which highlight the value of DNA-based NGS profiling for characterizing the genomic landscape and rec...
Aysu Sadioğlu, O. Ekinci, Nalan Akyurek· BMC Cancer· 0 citations
Highlights • Next-generation sequencing (NGS) on circulating tumor DNA (ctDNA) from 106 Bangladeshi NSCLC patients has been performed.• We found mutations in 85.8% of patients, and the most common mutated genes are TP53, EGFR, and KRAS.• We could identify most prevalent clinically important pathogenic variants, c.2155G...
Md. Al Amin, Manisha Das, Pradip Kumar Nath et al.· Translational Oncology· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.